Week In Review: Hansoh Signs $1.5 Billion Cross-Border Deal For AI-Drug Discovery With Atomwise
Article By:
ChinaBio® Today
Read
Saturday, September 14, 2019 4:53 PM EDT
China's Hansoh Pharma formed an AI-based small molecule drug discovery collaboration worth up to $1.5 billion with Atomwise of San Francisco.
Japan Drug Firm Bets $3 Billion On Castoffs And Hype
Article By:
Lipper Alpha Insight
Read
Monday, September 9, 2019 9:05 PM EDT
The lucrative deal with Sumitomo is just the treatment Roivant needs to keep its model ticking. But it’s unlikely to fix what ails its Japanese partner.
In this article: DNPUF
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By:
T.J. Hayes
Read
Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
E Portfolio Highlights - September 2019
Article By:
Ingrid Hendershot
Read
Monday, September 9, 2019 2:15 PM EDT
During the past three months, the S&P 500 Index rose 2.1% despite renewed concerns over a trade war and slowing global growth. The following high-quality stocks all generated solid 9% or better gains during the same period.
Week In Review: PAG Pays $540 Million For 58% Stake In Hisun BioRay, A China Biotech
Article By:
ChinaBio® Today
Read
Saturday, September 7, 2019 4:35 PM EDT
PAG, a Hong Kong PE firm, will pay $540 million to acquire a 58% stake in Hisun BioRay, a China biologics company developing autoimmune and oncology drugs.
E CGC: Better Safe Than Sorry
Article By:
Christian Stoyanov
Read
Saturday, September 7, 2019 3:52 PM EDT
Recently Canopy Growth Corp. (CGC) has reached its 12 month low, mainly due to excessive cash burns and disappointing results. Even so, I do not find solid underlying company fundamentals for investing in it.
In this article: CGC
E Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
Article By:
Terry Chrisomalis
Read
Thursday, September 5, 2019 8:46 AM EDT
Bellicum is a highly undervalued biotech. Especially, when you consider that it has two types of technology that can be utilized to potentially alter how CAR-T therapies are produced.
In this article: BLCM
The Stock Market Stands On A Precarious Scaffold
Article By:
Michele Schneider
Read
Sunday, September 1, 2019 10:15 AM EDT
In the current market, the price action and negative phases in the indices hang precariously. The bulls, nevertheless, continue to trust the scaffolding of low interest rates, hope for a resolution of tariffs and positive economic statistics.
Week In Review: HiFiBiO Raises $67 Million For Immune Modulator Portfolio
Article By:
ChinaBio® Today
Read
Saturday, August 31, 2019 4:14 PM EDT
Biotheus, a Guangdong biopharma, signed a $142 million deal for China rights to three bi-specifics based on a TNFR antibody from Alligator Bio of Stockholm.
In this article: LLY
Week In Review: Biotheus Acquires China Rights To Three Bi-specifics In $142 Million Deal
Article By:
ChinaBio® Today
Read
Saturday, August 24, 2019 5:15 PM EDT
Biotheus, a Guangdong biopharma, signed a $142 million deal for China rights to three bi-specifics based on a TNFR antibody from Alligator Bio of Stockholm.
In this article: LLY
Stock Charts To Watch - August 19, 2019
Video By:
Harry Boxer
Watch
Monday, August 19, 2019 5:14 PM EDT
Amyris, Inc. had a really good session on Monday, jumping 74 cents, or 20%, to 4.41, on 1.5 million shares. Arrowhead Pharmaceuticals, Neogen Corp., Perion Network, SunPower Corp., and XPO Logistics look good as well. Let's take a closer look